Camp4 Therapeutics Corporation
CAMP
$1.55
-$0.04-2.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.50M | 858.00K | 652.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.50M | 858.00K | 652.00K | -- | -- |
| Cost of Revenue | 10.34M | 10.15M | 10.00M | 9.70M | 9.39M |
| Gross Profit | -8.85M | -9.29M | -9.34M | -9.70M | -9.39M |
| SG&A Expenses | 4.18M | 3.81M | 4.69M | 3.81M | 3.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.53M | 13.96M | 14.69M | 13.52M | 12.66M |
| Operating Income | -13.03M | -13.10M | -14.03M | -13.52M | -12.66M |
| Income Before Tax | -12.59M | -12.43M | -13.28M | -13.48M | -12.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.59M | -12.43M | -13.28M | -13.48M | -12.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.59M | -12.43M | -13.28M | -13.48M | -12.58M |
| EBIT | -13.03M | -13.10M | -14.03M | -13.52M | -12.66M |
| EBITDA | -12.60M | -12.68M | -13.62M | -13.10M | -12.24M |
| EPS Basic | -0.62 | -0.62 | -0.77 | -24.19 | -26.00 |
| Normalized Basic EPS | -0.39 | -0.39 | -0.48 | -15.12 | -16.25 |
| EPS Diluted | -0.62 | -0.62 | -0.77 | -24.19 | -26.00 |
| Normalized Diluted EPS | -0.39 | -0.39 | -0.48 | -15.12 | -16.25 |
| Average Basic Shares Outstanding | 20.16M | 20.15M | 17.25M | 557.40K | 483.60K |
| Average Diluted Shares Outstanding | 20.16M | 20.15M | 17.25M | 557.40K | 483.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |